Skip to main content
. 2022 Feb 11;12:843299. doi: 10.3389/fonc.2022.843299

Figure 4.

Figure 4

The kinase inhibition activity of 1G to 3G EGFR TKIs against EGFR wild type (A) and p.L747P-mutant (B) cell lines.